The user experienced significant hair regrowth and increased confidence after 8 months using 5mg Minoxidil, 1.1mg Finasteride, and 1mg Biotin, with no side effects. The user received many compliments on their thicker hair and plans to get a haircut.
PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.
The user resumed finasteride and added 5mg oral minoxidil and biotin, noticing quick progress in hair regrowth. Other users discuss dosages and express surprise at the results.
Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.
The user shared their successful hair regrowth journey using minoxidil 5% twice daily and weekly microneedling. Other users suggested adding finasteride to maintain gains long-term.
The potential of using a specific antibody, HMI-115, as a treatment for hair loss alongside traditional treatments such as minoxidil and finasteride. The user suggests trying either a 240 mg or 30 mg dose to see if it works.
A user named "bmbshell" who was dealing with hair loss and initially tried to fix it with a hair system before deciding to try finasteride, dutasteride, minoxidil, microneedling, and biotin supplements. They documented their progress over the past 1 year and 3 months, showing how effective these treatments were in regrowing their hair.
User shared 1.5-year progress using 1mg finasteride, 15% minoxidil daily, and derma rolling weekly. Experienced initial shedding but achieved significant hair regrowth and improvement.
A person was concerned about applying minoxidil and tretinoin in a public airport bathroom, fearing judgment from others. Most responses reassured them that no one cares, suggesting they apply it in a stall or skip a dose without worry.
PP405's effectiveness in increasing hair density is questioned due to a small sample size, despite investment from Google Ventures. Users express skepticism and suggest waiting for more conclusive results.
The conversation is about a person's two-year hair regrowth progress using finasteride, minoxidil, ketoconazole, and microneedling. They are comparing their hair from April 21, 2022, to April 13, 2024.
Finasteride, minoxidil, and derma rolling are currently the best treatments for hair loss. New treatments like TDM-105795, GT20029, PP405, HMI 115, Tsuji, Scube 3, RU, JW0061, Topilutamide, and verteporfin show promise but have uncertain timelines.
The user reported hair regrowth after using 1 mg finasteride daily for 4 months, foam minoxidil twice daily for 6 months, and 5000 mcg biotin daily for 4 months. Commenters are impressed with the results and some are considering starting finasteride after seeing the progress.
User reported hair regrowth and thicker hair after using rosemary oil, zinc, biotin, vitamin D, and a better diet. They believe rosemary oil contributed the most to the improvement.
Procyanidin B2, a compound derived from Annurca apples, as a potential treatment for pattern hair loss. Several clinical studies were mentioned, which found that procyanidin B2 could increase hair growth, density, and keratin content. Other treatments such as Minoxidil, Finasteride, and RU58841 were not discussed.
Slow_Class_4465's progress using finasteride and minoxidil to address hair loss, which has resulted in drastic improvement. Other users have shared their experiences with the treatments, including possible side effects.
Triple Hair Inc. developed a new topical treatment, TH07, combining Finasteride, Latanoprost, and Minoxidil for androgenic alopecia. Users discussed its effectiveness compared to other treatments and shared their own product combinations.
The user is experiencing hair loss and has tried various treatments including topical and oral finasteride, minoxidil, dutasteride, and ketoconazole, but continues to lose hair. They are considering alternative solutions like hair systems due to the lack of improvement and a scalp condition called CVG.
Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.
The user is experiencing progress in hair growth using 0.5mg Finasteride, 5mg Minoxidil, and 1mg Biotin daily but is also developing gynecomastia. They plan to continue the treatment for six months unless the side effects worsen.
The conversation discusses experiences with hair loss treatments containing RootBioTec and Anagain. Users share their results and compare these treatments to Minoxidil, finasteride, and RU58841.
New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.
PP405 is discussed as a potential treatment for hair loss, with excitement about its promise but skepticism about its current effectiveness. Users mention combining it with treatments like minoxidil, finasteride, and microneedling, but emphasize it is not a cure.
The conversation is about hair regrowth progress using topical finasteride and minoxidil twice daily, with occasional microneedling. The user also uses Minoxidilmax and WOW Skin Science Apple Cider Vinegar Shampoo.
The conversation is about hair loss treatments, including minoxidil, finasteride, dutasteride, tretinoin, stemoxydine, adenosine, castor oil, baicalin, and bimatoprost. The user shares their nightly and morning routines and discusses the role of DHT in hair loss.
The conversation discusses the hair loss treatment Breezula by Cassiopea, which had a successful Phase II trial and is expected to start Phase III by the end of the year. Users are curious about the timeline for availability and note that it performs slightly better than finasteride at 6 months, slightly worse at 12 months, with the benefit of having no side effects.